Genetic neuromuscular disease

Genetic neuromuscular disease (Orphanet code 183497) is a broad classification category encompassing a large and heterogeneous group of inherited disorders that affect the neuromuscular system. These conditions impair the function of muscles, the nerves that control them (motor neurons and peripheral nerves), or the neuromuscular junction where nerve signals are transmitted to muscle fibers. This grouping includes hundreds of distinct genetic entities such as muscular dystrophies, congenital myopathies, hereditary motor and sensory neuropathies (e.g., Charcot-Marie-Tooth disease), spinal muscular atrophies, congenital myasthenic syndromes, and many others. The clinical features vary widely depending on the specific underlying condition but commonly include progressive muscle weakness, muscle wasting (atrophy), hypotonia (reduced muscle tone), fatigue, difficulty walking or with fine motor tasks, respiratory insufficiency, and in some cases cardiac involvement. Age of onset ranges from the neonatal period to late adulthood, and severity spans from mild functional limitation to life-threatening respiratory and cardiac complications. Inheritance patterns across this group include autosomal dominant, autosomal recessive, X-linked, and mitochondrial transmission, depending on the specific disease entity. Treatment approaches are disease-specific and may include physical therapy, respiratory support, orthopedic interventions, and pharmacological therapies. In recent years, gene-targeted therapies have emerged for select conditions within this group, such as nusinersen and onasemnogene abeparvovec for spinal muscular atrophy. Multidisciplinary care involving neurologists, pulmonologists, cardiologists, and rehabilitation specialists is typically recommended. Because this is a classification category rather than a single disease, patients should seek diagnosis of their specific genetic neuromuscular condition for tailored management and genetic counseling.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Genetic neuromuscular disease